Peak Asset Management Logo

 1 November, 2023

The 1st of November!

How on earth are we already here?

COMMODITY/FOREX/CRYPTO MARKET PRICES
Gold: US$1,996.51(+0.04%)
Silver: US$23.15 (-0.65%)
Nickel (3mth): US$18,079/t (-1.30%)
Copper (3mth): US$7,985.50/t (-0.58%)
Oil (WTI): US$82.64 (+0.41%)
Oil (Brent): US$86.49 (+0.19%)
Iron 62pc Fe: US$118.70/t (+0.13%)
AUD/USD: 0.6360 (-0.18%)
Bitcoin: US$34,120 (-0.11%)

Across markets

Australian shares are poised to open higher. US shares were higher after the latest data mostly matched expectations and investors positioned for the pending policymakers’ decision.

ASX futures up 35 points or 0.5% to 6818 near 7am AEDT.

Among the megacap techs, Tesla rebounded after a California jury found that the company’s AutoPilot technology was not at fault in an accident that resulted in the death of a driver and serious injuries to two passengers.

Nvidia mostly pared a near 5 per cent early drop after the Wall Street Journal reported that the company may lose up to $US5 billion of orders from Chinese companies because of new US export restrictions.

BHP will host its annual meeting at 10am in Adelaide.

Source: AFR

Want to join the Peak Community and get access to our “hand-picked” corporate deals?

Closer to Home
  • mRNA is set to be the new frontier in vaccines, but has serious side effects including inflammation
  • ASX listed Noxopharm has a program to tackle this problem
  • Stockhead reached out to Stockhead’s CEO, Gisela Mautner

Scientists have been studying Messenger RNA or mRNA for decades starting in the 1960s, but it took until the global Covid-19 pandemic of 2020 for the first mRNA vaccine to be brought to market.

In three short years however, mRNA vaccines have saved millions of lives, achieved household recognition, and produced two Nobel Laureates – Katalin Karikó and Drew Weissman.

But the future of mRNA vaccines is not limited to just Covid. Biotechs are already developing mRNA vaccines to protect against other viruses such as the flu, and even HIV.

Despite this huge potential, one of the biggest drawbacks of taking mRNA vaccines is that fragments of mRNA bind to inflammation receptors in the body causing overstimulation, which results in inflammation.

Although inflammation is a natural part of the immune response when the body detects foreign substances, there is growing awareness of the importance of reducing inflammation in mRNA vaccines.

Noxopharm (ASX:NOX) is the only listed company on the ASX which is tackling this side effect problem head-on.

Source:Stockhead

Follow Peak Asset

Recent Peak Deals

Company: Alderan Resources (ASX:AL8)
Sector: Lithium
Deal Type: Placement
Raise Amount: $1.75M
Latest Entry Price: $0.006 with a 1:2 AL8OA
Today’s Price Change: $0.012 Unchanged

Company: Terra Uranium (ASX:T92)
Sector: Uranium
Deal Type: IPO
Raise Amount: $7.5M
Latest Entry Price: $0.20
Today’s Price Change: $0.13 Unchanged

Company: Patagonia Lithium (ASX:PL3)
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.20
Today’s Price Change: $0.12 Unchanged

Company: Gold Mountain Limited (ASX:GMN)
Sector: Lithium
Deal Type: Placement
Raise Amount: $2.25M
Latest Entry Price: $0.0075
Today’s Price Change: $0.005 -16.67%

Company: Unith Ltd. (ASX:UNT)
Sector: AI/ChatGPT
Deal Type: Placement
Raise Amount: $4.5M
Latest Entry Price: $0.033 with a 1:1 UNTO
Today’s Price Change: $0.0200 -4.76%

Company: Volt Resources Ltd. (ASX:VRC)
Sector: Battery Metals
Deal Type: Placement
Raise Amount: $5.75M
Latest Entry Price: $0.011
Today’s Price Change: $0.007 Unchanged

Company: Castle Minerals Ltd. (ASX:CDT)
Sector: Battery Metals/Base Metals
Deal Type: Placement
Raise Amount: $1.52M
Latest Entry Price: $0.02 with a 2:3 CDTOA
Today’s Price Change: $0.01 Unchanged

Company: Avenira Ltd. (ASX:AEV)
Sector: Phosphate
Deal Type: Placement
Raise Amount: $2.1M
Latest Entry Price: $0.01 with a 1:2 AEVO
Today’s Price Change: $0.012 -7.69%

Company: Latrobe Magnesium Ltd. (ASX:LMG)
Sector: Magnesium
Deal Type: Placement
Raise Amount: $3M & $11.5M
Latest Entry Price: $0.10 with a 1:4 LMGO
Today’s Price Change: $0.047 +6.82%

Company: Askari Metals Ltd (ASX:AS2)
Sector: Mining
Deal Type: IPO
Raise Amount: $5.7M
Latest Entry Price: $0.35 with a 1:3 AS2O
Today’s Price Change: $0.16 +3.23%

Company: iCandy (ASX:ICI)
Sector: Gaming & Digital Advertising
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.02 with a 1:1 ICIOB
Today’s Price Change: $0.033 +22.22%

Company: Fatfish Group (ASX:FFG)
Sector: Fintech
Deal Type: Placement
Raise Amount: $1.5M
Latest Entry Price: $0.015 with a 1:2 FFGOA
Today’s Price Change: $0.011 Unchanged

Company: Paradigm Biopharma (ASX:PAR)
Sector: Biopharma
Deal Type: IPO Cornerstone
Raise Amount: $1M+
Latest Entry Price: $0.35
Today’s Price Change: $0.62 Unchanged

Company: ReNu Energy Limited (ASX:RNE)
Sector: Energy
Deal Type: Placement
Raise Amount: $1.46M
Latest Entry Price: $0.06 with a 1:1 RNEO
Today’s Price Change: $0.020 -13.04%

Company: Carly Holdings Ltd (ASX:CL8)
Sector: AI and Car subscription
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.025 with a 1:2 CL8O
Today’s Price Change: $0.015 Unchanged

Company: Avecho Biotechnology (ASX:AVE)
Sector: CBD
Deal Type: Placement
Raise Amount: $5M
Latest Entry Price: $0.006 with a 3:2 AVEOA
Today’s Price Change: $0.004 Unchanged

Company: ECS Botanics Holdings Ltd (ASX:ECS)
Sector: Medicinal Cannabis
Deal Type: Placement
Raise Amount: $6.6M
Latest Entry Price: $0.033 with 1:2 ECSO
Today’s Price Change: $0.023 Unchanged

If you would like more information on future Peak deals, please don’t hesitate to get in touch.

The trustee for Peak Asset Management Unit Trust (“Peak”) is a corporate authorised representative (#1295491) of Dayton Way Securities Pty Ltd (AFSL #382585).
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs.  Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances.  If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au  or by telephoning
Peak on 1300 304 460

Categories:

Tags:

No responses yet

Leave a Reply